FASENRA SCEI for Long-term Use

NCT03588546 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 653

Last updated 2025-09-02

No results posted yet for this study

Summary

The purpose of the investigation is to confirm the safety and efficacy under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Toshimitsu Tokimoto · AstraZeneca KK

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-31
Primary Completion
2024-09-10
Completion
2024-09-10

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03588546 on ClinicalTrials.gov